SCHEMBL4099113

SCHEMBL4099113

CC(C)Oc1ccc(-c2cc(C(=O)Nc3ccc(C(C)NC(=O)OC(C)(C)C)cc3)no2)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
HSD17B10 Q99714 3/20 0.48
KDM4E B2RXH2 2/20 0.48
HDAC1 Q13547 5/20 0.47
HDAC6 Q9UBN7 5/20 0.47
HDAC3 O15379 3/20 0.47
HDAC10 Q969S8 3/20 0.47
TP53 P04637 1/20 0.47
THRB P10828 1/20 0.47
HDAC2 Q92769 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099115 1.00 MAPT (0.49) MAPTHSD17B10KDM4EHDAC1HDAC6
SCHEMBL3931661 0.84 HDAC6 (0.53) MAPTHSD17B10KDM4EHDAC1HDAC6
SCHEMBL4093749 0.83 MAPT (0.56) MAPTHSD17B10KDM4ETP53THRB
SCHEMBL3935954 0.83 MAPT (0.56) MAPTHSD17B10KDM4ETP53THRB
SCHEMBL3935996 0.83 HSD17B10 (0.63) MAPTHSD17B10KDM4ETP53THRB
SCHEMBL13901891 0.82 MAPT (0.56) MAPTHSD17B10KDM4ETP53THRB
SCHEMBL3931658 0.81 MAPT (0.46) MAPTHSD17B10KDM4EHDAC1HDAC6
SCHEMBL13901888 0.80 MAPT (0.52) MAPTHSD17B10KDM4ETP53THRB
SCHEMBL13901887 0.80 MAPT (0.52) MAPTHSD17B10KDM4ETP53THRB
SCHEMBL3935956 0.78 MAPT (0.53) MAPTHSD17B10KDM4ETP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069288-A1 Novel therapeutic compounds MAP3K20, RPS6KB1, MAP3K1 MAPT 3755/4885HSD17B10 1621/4885KDM4E 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.